Circulating miR-200c-3p as a marker of metastatic disease at diagnosis in breast cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e12559-e12559
Author(s):  
Esther Navarro Manzano ◽  
Gines Luengo-Gil ◽  
Elisa Garcia-Garre ◽  
Maria Piedad Fernandez Perez ◽  
Ana Fernandez Sanchez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Disease ◽  
Predictive Value ◽  
Plasma Levels ◽  
Cancer Biology ◽  
Statistical Tests ◽  
Locally Advanced ◽  
Initial Diagnosis ◽  
Plasma Samples ◽  
Mesenchymal Transition

e12559 Background: MicroRNAs are involved in cancer biology through their role in regulation of protein expression. The miR-200 family plays a dual role in breast cancer (BC), both regulating epithelial to mesenchymal transition and promoting metastatic colonization. Plasma levels of miR-200 have been previously evaluated as prognostic factors in early and metastatic BC (MBC) but its role as a potential diagnostic marker is less well established. The aim of this study was to determine the potential diagnostic value of miR-200c-3p plasmatic levels in women with locally advanced and metastatic BC. Methods: We included 73 BC patients and 14 controls. Plasma samples were obtained at diagnosis, before treatment. RNA from plasma samples was extracted with NucleoSpin miRNA plasma (Macherey-Nagel). We analyzed expression levels of miR-200c-3p, which were relativized (2-ΔΔCT method) to miR-16. Non-parametric statistical tests were used to determine the association of miR-200c levels with clinical variables. Receiver-operating curves (ROC) were constructed and diagnostic ability evaluated. Kaplan-Meier curves and Cox models were used for survival analyses. Results: 73 BC patients were included: 36 locally advanced BC (LABC) and 37 MBC (7 recurrences and 30 MBC at initial diagnosis [MBCID]). Plasma miR-200c levels were significantly higher in MBC than in controls (p = 0.001) and in LABC (p = 0.001). We found differences neither for age nor for estrogen receptors, HER2, tumor subtype or histology. Overall and disease free survival did not differ by miR-200c levels in any of the groups. Among MBC patients, higher levels were observed in MBCID (p = 0.023). In the group of women with an initial diagnosis of BC (n = 65), high miR-200c levels (over 1st tertile) identified metastatic disease with a sensitivity of 90.0% (95%CI: 72.3-97.4%) and a specificity of 51.4% (95%CI: 34.3-68.3%); negative predictive value: 85.7%; positive predictive value: 61.4%; ROC AUC: 0.79. Conclusions: MiR-200c plasma levels are higher in BC patients with metastatic disease at diagnosis, and might be clinically useful to identify them. Further research on miR200c biological role in MBC and validation in larger populations with sequential samples are warranted.

scholarly journals Incidence of internal mammary node in locally advanced breast cancer and its correlation with metastatic disease: a retrospective observational study

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190098
Author(s):  
Somesh Singh ◽  
Subhash K Ramani ◽  
Ashita Rastogi ◽  
Meenakshi H Thakur
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Metastatic Disease ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Advanced Breast ◽  
Internal Mammary Nodes ◽  
Imaging Results ◽  
Internal Mammary

Objective: To determine incidence of internal mammary nodes (IMN) at baseline CT of locally advanced breast cancer (LABC) and ascertain prognostic implication. Methods and materials: Retrospective review of all LABC patients from 1 January 2012 through 31 December 2014 was performed after approval from institutional review board. CTs of 182 patients enrolled were reviewed by two radiologists independently, and IMNs were documented based on size, location and relation with location of breast primary. 3-year follow-up was analysed and incidence of metastases was calculated as overall incidence, incidence in patients with and without discernible IMN at baseline imaging. Results are presented as numbers and percentages. Differences in metastases of two groups were compared using χ2 test. 95% CI was calculated and p < 0.05 was considered significant. Results: 77 of 182 had identifiable IMN (42.3% incidence). Majority of identifiable nodes were on ipsilateral side of primary (incidence 90.90%) with higher incidence in patients with upper-outer quadrant tumours (55.9%). Majority were seen in second intercostal space (44.4%). 36 (19.7%) developed distant metastases within 3 years of therapy. Of these, 21 (27.3%) had IMN as compared with 15 (14.3 %) without IMN on baseline imaging. Patients with identifiable IMN on baseline CT had significantly higher incidence of distant metastases (p = 0.0321). Conclusion: Significant number LABC patients have identifiable IMN on baseline imaging with patients showing IMN on baseline CT showing significantly higher rate of metastatic disease following therapy. Advances in knowledge: Many LABC patients have identifiable IMNs on baseline imaging which show higher incidence of subsequent metastatic disease.

scholarly journals LncRNA PAPAS may promote triple-negative breast cancer by downregulating miR-34a

2019 ◽  
Vol 47 (8) ◽  
pp. 3709-3718 ◽  
Author(s):  
Yan Kong ◽  
Cuizhi Geng ◽  
Qian Dong
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Cancer Biology ◽  
Triple Negative ◽  
Migration And Invasion ◽  
Cancer Cell Proliferation ◽  
Healthy Controls ◽  
Plasma Samples

Objective To investigate the role of promoter and pre-rRNA antisense (PAPAS) long noncoding (Lnc) RNA in cancer biology. Methods Tumour and tumour-adjacent healthy tissue biopsies from patients with triple-negative breast cancer (TNBC), and plasma samples from these patients plus healthy controls, were assessed for PAPAS and microRNA (miR)-34a. Effects of PAPAS and miR-34a overexpression were also investigated in vitro. Results PAPAS was upregulated in tumour tissues of patients with TNBC versus tumour-adjacent healthy tissues. Plasma PAPAS levels were also upregulated in patients with TNBC versus healthy controls. Levels of PAPAS in tumour tissue was significantly positively correlated with PAPAS levels in plasma from patients with TNBC. MiR-34a was downregulated in tumour tissues versus adjacent healthy tissues, and was significantly correlated with PAPAS in tumour tissues. PAPAS overexpression in vitro was associated with miR-34a inhibition, while miR-34a failed to significantly affect PAPAS levels. PAPAS overexpression promoted in vitro migration and invasion of TNBC cells, while miR-34a overexpression was inhibitory. MiR-34a overexpression decreased the enhanced cell migration and invasion associated with PAPAS overexpression. PAPAS overexpression showed no significant effects on cancer-cell proliferation. Conclusion LncRNA PAPAS may promote TNBC by downregulating miR-34a.

scholarly journals The lingering mysteries of metastatic recurrence in breast cancer

2020 ◽  
Vol 124 (1) ◽  
pp. 13-26
Author(s):  
Alessandra I. Riggio ◽  
Katherine E. Varley ◽  
Alana L. Welm
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Systemic Therapy ◽  
Initial Diagnosis ◽  
Diagnosis And Treatment ◽  
Breast Cancer Patients ◽  
Key Factors ◽  
Metastatic Recurrence ◽  
Metastatic Relapse

AbstractDespite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.

PR136 PREDICTIVE VALUE OF MRNA EXPRESSION OF TUBβIII GENE IN THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER

The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S68
Author(s):  
Tatiana Semiglazova ◽  
Petr Krivorotko ◽  
Ekaterina Busko ◽  
Sergey Novikov ◽  
Veronika Klimenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Mrna Expression ◽  
Predictive Value ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast

Assessing the use of routine abdominal CT in staging evaluation of patients with primary breast cancer.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 3-3
Author(s):  
Stuart-Allison Moffat Staley
Keyword(s):  
Breast Cancer ◽  
Ct Scan ◽  
Metastatic Disease ◽  
Predictive Value ◽  
Primary Breast Cancer ◽  
Chest Ct ◽  
Disease Spread ◽  
Newly Diagnosed ◽  
Abdominal Ct ◽  
Axillary Nodes

3 Background: The purpose of this study was to determine the utility of routine abdominal CT in the staging evaluation of women with newly diagnosed primary breast cancer given no detectable disease beyond the ipsilateral axillary nodes on chest CT. Methods: The chest and abdominal CT scans from 440 patients over a 10-year period were reviewed. The presence of definite or possible metastatic disease in the axillary nodes, chest wall, internal mammary nodes, mediastinal nodes, lungs, liver and adrenals were recorded for each patient. Cross tabulation bivariate analysis as well as a chi-square test were performed to characterize the relationship between detection of disease in the chest and disease in the abdomen. Results: Of the 440 patients reviewed, the following were found to have detectable metastatic disease by CT scan: axillary nodes 258 of 440 (56.46%), chest wall 40 of 440 (9.10%), internalmammary nodes 8 of 440 (1.82%), mediastinal nodes 29 of 440 (6.59%), lung 25 of 440 (5.68%), liver 12 of 437 (2.73%), and adrenals 8 of 440 (1.82%). In total, 81 patients had disease detectable in the chest beyond the ipsilateral axillary nodes, and only 12 patients had detectable disease spread in the abdomen. Of the 359 patients who had a negative chest CT, only 1 patient had detectable or possible metastatic disease spread on abdominal CT, resulting in a 99.70% negative predictive value (p < 0.001). Conclusions: The routine use of abdominal CT in women with newly diagnosed primary breast cancer and no detectable disease beyond the ipsilateral axillary nodes on staging chest CT scan has little value with a 99.70% negative predictive value. We recommend that if a negative CT scan of the patient’s chest yields no detectable disease beyond the axillary nodes, then further CT imaging of the abdomen is of no additional benefit to the patient. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document